January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopm …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news